The medical community is favorably impressed with Kaletra (lopinavir, formerly ABT-378
, the newly-approved "second generation" protease inhibitor.
It's relatively easy to achieve very high concentrations of ABT-378
when given twice a day and possibly even once a day," Dr.
Researchers reported on several new drugs--such as ABT-378
from Abbott Laboratories and T-20 from Trimeris Inc.